Clinical trials: Attention Deficits
Attention Deficit Hyperactivity Disorder
Pilot Feasibility Study of Neurofeedback for Attention Deficit Hyperactivity Disorder (ADHD)
Neurofeedback is increasingly advocated for treatment of ADHD despite a thin evidence base. The numerous open and partially controlled studies suffer serious design flaws.
- Trial name
- NCT00886483
- Testing
- Active Neurofeedback
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- L. Eugene Arnold
Autism Spectrum Disorder, Attention Deficit Hyperactivity Disorder
A SMART Design to Improve Sleep Disturbance in Adolescents With Neurodevelopmental Disorders
The objective of this K01 study was to pilot a sequential, multiple assignment, randomized trial (SMART) design to compare the impact of a sequence of sleep interventions, based on participant treatment response, to optimize…
- Conditions
- Autism Spectrum Disorder, Attention Deficit Hyperactivity Disorder, Sleep Disturbance
- Trial name
- NCT03730194
- Testing
- Melatonin, Bedtime Bank
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Nebraska
Intermittent Explosive Disorder, Childhood Aggression
Intuniv vs Placebo in the Treatment of Childhood Intermittent Explosive Disorder
Children with explosive aggression are often rejected by their peers, placed in special classroom, and contribute to family discord. When psychotherapy and family therapy is unsuccessful, medications are often used.
- Conditions
- Intermittent Explosive Disorder, Childhood Aggression, Oppositional Defiant Disorder, Attention Deficit Disorder
- Trial name
- NCT02048241
- Testing
- Parent Management Training, Intuniv
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- New York State Psychiatric Institute
Attention Deficit Disorder With Hyperactivity
TRI102 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD)
The purpose of this study is to determine whether TRI102 is effective in the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children ages 6-12.
- Trial name
- NCT02083783
- Testing
- TRI102
- Where
- 5 sites in United States
- Volunteers
- 108 people
- Sponsor
- Tris Pharma, Inc.